97 results on '"biotherapeutics"'
Search Results
2. Plant-derived nanoparticles and plant virus nanoparticles: Bioactivity, health management, and delivery potential.
- Author
-
Liu, Cun, Yu, Yang, Fang, Liguang, Wang, Jia, Sun, Chunjie, Li, Huayao, Zhuang, Jing, and Sun, Changgang
- Subjects
- *
PLANT viruses , *DRUG delivery systems , *CELL communication , *CHARACTERISTIC functions , *PATHOGENIC microorganisms - Abstract
Natural plants have acquired an increasing attention in biomedical research. Recent studies have revealed that plant-derived nanoparticles (PDNPs), which are nano-sized membrane vesicles released by plants, are one of the important material bases for the health promotion of natural plants. A great deal of research in this field has focused on nanoparticles derived from fresh vegetables and fruits. Generally, PDNPs contain lipids, proteins, nucleic acids, and other active small molecules and exhibit unique biological regulatory activity and editability. Specifically, they have emerged as important mediators of intercellular communication, and thus, are potentially suitable for therapeutic purposes. In this review, PDNPs were extensively explored; by evaluating them systematically starting from the origin and isolation, toward their characteristics, including morphological compositions, biological functions, and delivery potentials, as well as distinguishing them from plant-derived exosomes and highlighting the limitations of the current research. Meanwhile, we elucidated the variations in PDNPs infected by pathogenic microorganisms and emphasized on the biological functions and characteristics of plant virus nanoparticles. After clarifying these problems, it is beneficial to further research on PDNPs in the future and develop their clinical application value. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity.
- Author
-
Siegel, Michel, Bolender, Anna-Lena, Ducret, Axel, Fraidling, Johannes, Hartman, Katharina, Looney, Cary M., Rohr, Olivier, Hickling, Timothy P., Kettenberger, Hubert, Lechmann, Martin, Marban-Doran, Céline, and Kraft, Thomas E.
- Subjects
PEPTIDES ,DENDRITIC cells ,IMMUNE response ,SURFACE charges ,T cells - Abstract
Introduction: Immunogenicity, the unwanted immune response triggered by therapeutic antibodies, poses significant challenges in biotherapeutic development. This response can lead to the production of anti-drug antibodies, potentially compromising the efficacy and safety of treatments. The internalization of therapeutic antibodies into dendritic cells (DCs) is a critical factor influencing immunogenicity. Using monoclonal antibodies, with differences in non-specific cellular uptake, as tools to explore the impact on the overall risk of immunogenicity, this study explores how internalization influences peptide presentation and subsequently T cell activation. Materials and methods: To investigate the impact of antibody internalization on immunogenicity, untargeted toolantibodies with engineered positive or negative charge patches were utilized. Immature monocyte-derived DCs (moDCs), known for their physiologically relevant high endocytic activity, were employed for internalization assays, while mature moDCs were used for MHC-II associated peptide proteomics (MAPPs) assays. In addition to the lysosomal accumulation and peptide presentation, subsequent CD4+ T cell activation has been assessed. Consequently, a known CD4+ T cell epitope from ovalbumin was inserted into the tool antibodies to evaluate T cell activation on a single, shared epitope. Results: Antibodies with positive charge patches exhibited higher rates of lysosomal accumulation and epitope presentation compared to those with negative charge patches or neutral surface charge. Furthermore, a direct correlation between internalization rate and presentation on MHC-II molecules could be established. To explore the link between internalization, peptide presentation and CD4+ T cell activation, tool antibodies containing the same OVA epitope were used. Previous observations were not altered by the insertion of the OVA epitope and ultimately, an enhanced CD4+ T cell response correlated with increased internalization in DCs and peptide presentation. Discussion: These findings demonstrate that the biophysical properties of therapeutic antibodies, particularly surface charge, play a crucial role in their internalization into DCs. Antibodies internalized faster and processed by DCs, are also more prone to be presented on their surface leading to a higher risk of triggering an immune response. These insights underscore the importance of considering antibody surface charge and other properties that enhance cellular accumulation during the preclinical development of biotherapeutics to mitigate immunogenicity risks. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics.
- Author
-
Siegel, Michel, Padamsey, Aman, Bolender, Anna-Lena, Hargreaves, Patrick, Fraidling, Johannes, Ducret, Axel, Hartman, Katharina, Looney, Cary M., Bertinetti-Lapatki, Cristina, Rohr, Olivier, Hickling, Timothy P., Kraft, Thomas E., and Marban-Doran, Céline
- Subjects
MONONUCLEAR leukocytes ,IMMUNE response ,DENDRITIC cells ,DRUG bioavailability ,THERAPEUTIC use of proteins - Abstract
Introduction: Immunogenicity refers to the ability of a substance, such as a therapeutic drug, to elicit an immune response. While beneficial in vaccine development, undesirable immunogenicity can compromise the safety and efficacy of therapeutic proteins by inducing anti-drug antibodies (ADAs). These ADAs can reduce drug bioavailability and alter pharmacokinetics, necessitating comprehensive immunogenicity risk assessments starting at early stages of drug development. Given the complexity of immunogenicity, an integrated approach is essential, as no single assay can universally recapitulate the immune response leading to the formation of anti-drug antibodies. Methods: To better understand the Dendritic Cell (DC) contribution to immunogenicity, we developed two flow cytometry-based assays: the DC internalization assay and the DC activation assay. Monocyte-derived dendritic cells (moDCs) were generated from peripheral blood mononuclear cells (PBMCs) and differentiated over a five-day period. The internalization assay measured the accumulation rate of therapeutic antibodies within moDCs, while the activation assay assessed the expression of DC activationmarkers such as CD40, CD80, CD86, CD83, and DC-SIGN (CD209). To characterize these two assays further, we used a set of marketed therapeutic antibodies. Results: The study highlights that moDCs differentiated for 5 days from freshly isolated monocytes were more prone to respond to external stimuli. The internalization assay has been shown to be highly sensitive to the molecule tested, allowing the use of only 4 donors to detect small but significant differences. We also demonstrated that therapeutic antibodies were efficiently taken up by moDCs, with a strong correlation with their peptide presentation on MHC-II. On the other hand, by monitoring DC activation through a limited set of activation markers including CD40, CD83, and DC-SIGN, the DC activation assay has the potential to compare a series of compounds. These two assays provide a more comprehensive understanding of DC function in the context of immunogenicity, highlighting the importance of both internalization and activation processes in ADA development. Discussion: The DC internalization and activation assays described here address key gaps in existing immunogenicity assessment methods by providing specific and reliable measures of DC function. The assays enhance our ability to pre-clinically evaluate the immunogenic potential of biotherapeutics, thereby improving their safety and efficacy. Future work should focus on further validating these assays and integrating them into a holistic immunogenicity risk assessment framework. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures.
- Author
-
Jain, Smriti, Shukla, Adarsh Kumar, Deepika, Panwar, Surbhi, Kumari, Anita, Yadav, Ashok Kumar, and Kumar, Ashwani
- Subjects
GUT microbiome ,JUNK food ,PROBIOTICS ,PEPTIDES ,DIETARY patterns - Abstract
Human intestinal gut microbiota harbors complex and diverse microbes that play an important role in maintaining the homeostasis of the intestinal microenvironment in humans. The rise in mortality and morbidity rates among humans because of the increased incidence of food‐borne pathogens and the habits of individuals to eat junk food poses greater concerns and needs to be addressed. Bioengineering of probiotics has enabled the researchers to advance their research by developing probiotics with more functionalities. Moreover, GLP‐1 peptides which are incretin hormones have been shown to be more effective when combined with engineered probiotics. Various studies have shown its effectiveness in diabetic mice where human‐modified GLP‐1 produced long‐lasting benefits and research is going on to study its role in other diseases. The role of designer probiotics in treating and preventing diseases have been of much interest in recent times. However, the role of GLP‐1 peptides in treating diseases and their efficacy in combination with next‐gen biotherapeutics have received little attention. Thus, this review enlightens about the baseline knowledge as well as knowledge gaps related to conventional and genetically engineered probiotics. It also discusses the effect of GLP‐1 peptides in combination with bioengineered probiotics to prevent and treat diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Pulmonary Inhalation of Biotherapeutics: A Systematic Approach to Understanding the Effects of Atomisation Gas Flow Rate on Particle Physiochemical Properties and Retained Bioactivity.
- Author
-
Foley, Laura, Ziaee, Ahmad, Walker, Gavin, and O'Reilly, Emmet
- Subjects
- *
GAS flow , *GRANULAR flow , *ENGINEERS , *LYSOZYMES , *BIOPHARMACEUTICS - Abstract
The identification of spray-drying processing parameters capable of producing particles suitable for pulmonary inhalation with retained bioactivity underpins the development of inhalable biotherapeutics. Effective delivery of biopharmaceuticals via pulmonary delivery routes such as dry powder inhalation (DPI) requires developing techniques that engineer particles to well-defined target profiles while simultaneously minimising protein denaturation. This study examines the simultaneous effects of atomisation gas flow rate on particle properties and retained bioactivity for the model biopharmaceutical lysozyme. The results show that optimising the interplay between atomisation gas flow rate and excipient concentration enables the production of free-flowing powder with retained bioactivity approaching 100%, moisture content below 4%, and D50 < 4 µm, at yields exceeding 50%. The developed methodologies inform the future design of protein-specific spray-drying parameters for inhalable biotherapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Limosilactobacillus fermentum Strains as Novel Probiotic Candidates to Promote Host Health Benefits and Development of Biotherapeutics: A Comprehensive Review.
- Author
-
de Luna Freire, Micaelle Oliveira, Cruz Neto, José Patrocínio Ribeiro, de Albuquerque Lemos, Deborah Emanuelle, de Albuquerque, Thatyane Mariano Rodrigues, Garcia, Estefânia Fernandes, de Souza, Evandro Leite, and de Brito Alves, José Luiz
- Abstract
Fruits and their processing by-products are sources of potentially probiotic strains. Limosilactobacillus (L.) fermentum strains isolated from fruit processing by-products have shown probiotic-related properties. This review presents and discusses the results of the available studies that evaluated the probiotic properties of L. fermentum in promoting host health benefits, their application by the food industry, and the development of biotherapeutics. The results showed that administration of L. fermentum for 4 to 8 weeks promoted host health benefits in rats, including the modulation of gut microbiota, improvement of metabolic parameters, and antihypertensive, antioxidant, and anti-inflammatory effects. The results also showed the relevance of L. fermentum strains for application in the food industry and for the formulation of novel biotherapeutics, especially nutraceuticals. This review provides evidence that L. fermentum strains isolated from fruit processing by-products have great potential for promoting host health and indicate the need for a translational approach to confirm their effects in humans using randomized, double-blind, placebo-controlled trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates.
- Author
-
Usdin, Maxime, Quarmby, Valerie, Zanghi, James, Bernaards, Coen, Liao, Laura, Laxamana, Joel, Wu, Benjamin, Swanson, Steven, Song, Yuan, and Siguenza, Patty
- Abstract
Measurement of anti-drug antibodies (ADA) to assess the incidence of ADA in a clinical trial is a critical step in immunogenicity assessment during the development of a protein therapeutic. We developed novel graphical approaches to illustrate clinical trial ADA data for the PD-L1 inhibitor atezolizumab (Tecentriq) that included a systematic analysis of the impact of the timing of ADA sampling and ADA assay drug tolerance on reported ADA incidence. We found that approaches used across the industry for ADA incidence analysis provide a limited view of immunogenicity in oncology studies, where ADA detection may be confounded by both drug dosage and patient attrition. Moreover, these approaches can miss important temporal information about the immune response. Our results demonstrated that the methodology of ADA assessment for the atezolizumab program was specifically designed to capture most ADA responses to ensure accurate reporting of ADA incidence. We further showed that the use of sparse sampling and/or ADA test methods with insufficient drug tolerance may result in a significant underreporting of ADA incidence. We conclude that the comparison of ADA incidence between different drugs can be highly misleading and that a test method with appropriate sensitivity in the presence of the drug and a clinical sampling scheme that is aligned with ADA responses to a drug is required to accurately report ADA incidence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures
- Author
-
Smriti Jain, Adarsh Kumar Shukla, Deepika, Surbhi Panwar, Anita Kumari, Ashok Kumar Yadav, and Ashwani Kumar
- Subjects
bioengineered probiotics ,biotherapeutics ,GLP‐1 ,GLP‐1 receptors ,probiotics ,Food processing and manufacture ,TP368-456 - Abstract
Abstract Human intestinal gut microbiota harbors complex and diverse microbes that play an important role in maintaining the homeostasis of the intestinal microenvironment in humans. The rise in mortality and morbidity rates among humans because of the increased incidence of food‐borne pathogens and the habits of individuals to eat junk food poses greater concerns and needs to be addressed. Bioengineering of probiotics has enabled the researchers to advance their research by developing probiotics with more functionalities. Moreover, GLP‐1 peptides which are incretin hormones have been shown to be more effective when combined with engineered probiotics. Various studies have shown its effectiveness in diabetic mice where human‐modified GLP‐1 produced long‐lasting benefits and research is going on to study its role in other diseases. The role of designer probiotics in treating and preventing diseases have been of much interest in recent times. However, the role of GLP‐1 peptides in treating diseases and their efficacy in combination with next‐gen biotherapeutics have received little attention. Thus, this review enlightens about the baseline knowledge as well as knowledge gaps related to conventional and genetically engineered probiotics. It also discusses the effect of GLP‐1 peptides in combination with bioengineered probiotics to prevent and treat diseases.
- Published
- 2024
- Full Text
- View/download PDF
10. Secretome from iPSC-derived MSCs exerts proangiogenic and immunosuppressive effects to alleviate radiation-induced vascular endothelial cell damage
- Author
-
Kshama Gupta, Ralph B. Perkerson, Tammee M. Parsons, Ramacharan Angom, Danilyn Amerna, Jeremy D. Burgess, Yingxue Ren, Pamela J. McLean, Debabrata Mukhopadhyay, Prasanna Vibhute, Zbigniew K. Wszolek, Abba C. Zubair, Alfredo Quiñones-Hinojosa, and Takahisa Kanekiyo
- Subjects
iPSC-MSC ,Radiation therapy ,Angiogenesis ,Inflammation ,Secretome ,Biotherapeutics ,Medicine (General) ,R5-920 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Radiation therapy is the standard of care for central nervous system tumours. Despite the success of radiation therapy in reducing tumour mass, irradiation (IR)-induced vasculopathies and neuroinflammation contribute to late-delayed complications, neurodegeneration, and premature ageing in long-term cancer survivors. Mesenchymal stromal cells (MSCs) are adult stem cells that facilitate tissue integrity, homeostasis, and repair. Here, we investigated the potential of the iPSC-derived MSC (iMSC) secretome in immunomodulation and vasculature repair in response to radiation injury utilizing human cell lines. Methods We generated iPSC-derived iMSC lines and evaluated the potential of their conditioned media (iMSC CM) to treat IR-induced injuries in human monocytes (THP1) and brain vascular endothelial cells (hCMEC/D3). We further assessed factors in the iMSC secretome, their modulation, and the molecular pathways they elicit. Results Increasing doses of IR disturbed endothelial tube and spheroid formation in hCMEC/D3. When IR-injured hCMEC/D3 (IR ≤ 5 Gy) were treated with iMSC CM, endothelial cell viability, adherence, spheroid compactness, and proangiogenic sprout formation were significantly ameliorated, and IR-induced ROS levels were reduced. iMSC CM augmented tube formation in cocultures of hCMEC/D3 and iMSCs. Consistently, iMSC CM facilitated angiogenesis in a zebrafish model in vivo. Furthermore, iMSC CM suppressed IR-induced NFκB activation, TNF-α release, and ROS production in THP1 cells. Additionally, iMSC CM diminished NF-kB activation in THP1 cells cocultured with irradiated hCMEC/D3, iMSCs, or HMC3 microglial lines. The cytokine array revealed that iMSC CM contains the proangiogenic and immunosuppressive factors MCP1/CCL2, IL6, IL8/CXCL8, ANG (Angiogenin), GROα/CXCL1, and RANTES/CCL5. Common promoter regulatory elements were enriched in TF-binding motifs such as androgen receptor (ANDR) and GATA2. hCMEC/D3 phosphokinome profiling revealed increased expression of pro-survival factors, the PI3K/AKT/mTOR modulator PRAS40 and β-catenin in response to CM. The transcriptome analysis revealed increased expression of GATA2 in iMSCs and the enrichment of pathways involved in RNA metabolism, translation, mitochondrial respiration, DNA damage repair, and neurodevelopment. Conclusions The iMSC secretome is a comodulated composite of proangiogenic and immunosuppressive factors that has the potential to alleviate radiation-induced vascular endothelial cell damage and immune activation.
- Published
- 2024
- Full Text
- View/download PDF
11. Secretome from iPSC-derived MSCs exerts proangiogenic and immunosuppressive effects to alleviate radiation-induced vascular endothelial cell damage.
- Author
-
Gupta, Kshama, Perkerson III, Ralph B., Parsons, Tammee M., Angom, Ramacharan, Amerna, Danilyn, Burgess, Jeremy D., Ren, Yingxue, McLean, Pamela J., Mukhopadhyay, Debabrata, Vibhute, Prasanna, Wszolek, Zbigniew K., Zubair, Abba C., Quiñones-Hinojosa, Alfredo, and Kanekiyo, Takahisa
- Subjects
- *
VASCULAR endothelial cells , *ANDROGEN receptors , *GENE expression , *STEM cells , *PREMATURE aging (Medicine) , *RNA metabolism , *DNA repair - Abstract
Background: Radiation therapy is the standard of care for central nervous system tumours. Despite the success of radiation therapy in reducing tumour mass, irradiation (IR)-induced vasculopathies and neuroinflammation contribute to late-delayed complications, neurodegeneration, and premature ageing in long-term cancer survivors. Mesenchymal stromal cells (MSCs) are adult stem cells that facilitate tissue integrity, homeostasis, and repair. Here, we investigated the potential of the iPSC-derived MSC (iMSC) secretome in immunomodulation and vasculature repair in response to radiation injury utilizing human cell lines. Methods: We generated iPSC-derived iMSC lines and evaluated the potential of their conditioned media (iMSC CM) to treat IR-induced injuries in human monocytes (THP1) and brain vascular endothelial cells (hCMEC/D3). We further assessed factors in the iMSC secretome, their modulation, and the molecular pathways they elicit. Results: Increasing doses of IR disturbed endothelial tube and spheroid formation in hCMEC/D3. When IR-injured hCMEC/D3 (IR ≤ 5 Gy) were treated with iMSC CM, endothelial cell viability, adherence, spheroid compactness, and proangiogenic sprout formation were significantly ameliorated, and IR-induced ROS levels were reduced. iMSC CM augmented tube formation in cocultures of hCMEC/D3 and iMSCs. Consistently, iMSC CM facilitated angiogenesis in a zebrafish model in vivo. Furthermore, iMSC CM suppressed IR-induced NFκB activation, TNF-α release, and ROS production in THP1 cells. Additionally, iMSC CM diminished NF-kB activation in THP1 cells cocultured with irradiated hCMEC/D3, iMSCs, or HMC3 microglial lines. The cytokine array revealed that iMSC CM contains the proangiogenic and immunosuppressive factors MCP1/CCL2, IL6, IL8/CXCL8, ANG (Angiogenin), GROα/CXCL1, and RANTES/CCL5. Common promoter regulatory elements were enriched in TF-binding motifs such as androgen receptor (ANDR) and GATA2. hCMEC/D3 phosphokinome profiling revealed increased expression of pro-survival factors, the PI3K/AKT/mTOR modulator PRAS40 and β-catenin in response to CM. The transcriptome analysis revealed increased expression of GATA2 in iMSCs and the enrichment of pathways involved in RNA metabolism, translation, mitochondrial respiration, DNA damage repair, and neurodevelopment. Conclusions: The iMSC secretome is a comodulated composite of proangiogenic and immunosuppressive factors that has the potential to alleviate radiation-induced vascular endothelial cell damage and immune activation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Optimization, physicochemical stability and in vivo study of alginate-chitosan composites as nanocarriers for low molecular weight angiotensin I-converting enzyme (ACE)-inhibitory peptide.
- Author
-
Shehu Muhammad Auwal, Siti Balqis Muhammad Ghanisma, and Nazamid Saari
- Subjects
- *
BIOTHERAPY , *ALGINATES , *IN vitro studies , *T-test (Statistics) , *DATA analysis , *HYPERTENSION , *ACE inhibitors , *FISHER exact test , *ANTIHYPERTENSIVE agents , *IN vivo studies , *NANOMEDICINE , *DRUG delivery systems , *DESCRIPTIVE statistics , *POLYSACCHARIDES , *PEPTIDES , *BIOMEDICAL materials , *RATS , *FOOD industry , *CALCIUM chloride , *DRUG efficacy , *ANIMAL experimentation , *ANALYSIS of variance , *STATISTICS , *BIOSIMILARS , *DATA analysis software , *NANOPARTICLES , *ANGIOTENSIN I , *ANALYTICAL chemistry , *PHARMACODYNAMICS , *EVALUATION - Abstract
Chitosan and alginate, are non-toxic and biodegradable polymers used to enhance the stability of biotherapeutics by loading them into nanocarriers. In this study, the stone fish-derived low molecular weight peptide (Ala-Leu-Gly-Pro-Gln-Phe-Tyr), exhibited an in vitro ACE-inhibitory activity of 94.43 ± 2.05% and an IC50 of 0.012 ± 0.001 mM. The peptide was encapsulated via ionic gelation with alginate followed by polyelectrolyte complexation with chitosan. The resulting ACE-inhibitory peptide-loaded alginate-chitosan nanoparticles (ACE-I-ALG-CS NPs) were optimized to achieve small particle size (212.60 nm) and high encapsulation efficiency (EE, 74.48%). This was based on an optimum chitosan concentration (0.420%w/v), homogenization speed (6000 rpm), and homogenization time (30 min) using Box Behnken experimental design (BBED). Characterization of the ACE-I-ALG-CS NPs revealed a spherical, monodispersed morphology with high physicochemical stability during storage at 2 °C, 7 °C, and 12 °C for 12 weeks. Moreover, the in vivo study conducted on spontaneously hypertensive rats (SHRs) demonstrated a significantly higher (p < 0.05) systolic blood pressure (SBP)-lowering effect of the ACE-I-ALG-CS NPs compared to captopril and unencapsulated peptide. Hence, alginate and chitosan can be used as biocompatible coating materials to enhance the stability and in vivo anti-hypertensive effect of Ala-Leu-Gly-Pro-Gln-Phe-Tyr through encapsulation, thereby making it potentially valuable for various applications in pharmaceuticals and food industry. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Evaluation of resazurin phenoxazine dye as a highly sensitive cell viability potency assay for natural killer cell‐derived extracellular vesicle‐based cancer biotherapeutics.
- Author
-
St‐Denis‐Bissonnette, Frederic, Qiu, Shirley, Cummings, Sarah E., Kirkby, Melanie, Haile, Yohannes, Wassmer, Sarah, Muradia, Gauri, Mehic, Jelica, Stalker, Andrew, Shrestha, Amit, Ardolino, Michele, Lee, Seung‐Hwan, Burger, Dylan, Wang, Lisheng, and Lavoie, Jessie R.
- Subjects
- *
CELL survival , *CANCER cell analysis , *RESAZURIN , *CYTOTOXINS , *EXTRACELLULAR vesicles , *LACTATE dehydrogenase - Abstract
Natural killer cell‐derived extracellular vesicles (NK‐EVs) are candidate biotherapeutics against various cancers. However, standardised potency assays are necessary for a reliable assessment of NK‐EVs' cytotoxicity. This study aims to thoroughly evaluate a highly sensitive resazurin phenoxazine‐based cell viability potency assay (measurement of the cellular redox metabolism) for quantifying the cytotoxicity of NK‐EVs against leukaemia K562 cells (suspension model) and breast cancer MDA‐MB‐231 cells (adherent model) in vitro. The assay was evaluated based on common analytical parameters setforth by regulatory guidelines, including specificity, selectivity,accuracy, precision, linearity, range and stability. Our results revealed that this resazurin‐based cell viability potency assay reliably and reproducibly measured a dose‐response of NK‐EVs' cytotoxic activity against both cancer models. The assay showed precision with 5% and 20% variation for intra‐run and inter‐run variability. The assay signal showed specificity and selectivity of NK‐EVs against cancer target cells, as evidenced by the diminished viability of cancer cells following a 5‐hour treatment with NK‐EVs, without any detectable interference or background. The linearity analysis of target cancer cells revealed strong linearity for densities of 5000 K562 and 1000 MDA‐MB‐231 cells per test with a consistent range. Importantly, NK‐EVs' dose‐response for cytotoxicity showed a strong correlation (|ρ| ∼ 0.8) with the levels of known cytotoxic factors associated with the NK‐EVs' corona (FasL, GNLY, GzmB, PFN and IFN‐γ), thereby validating the accuracy of the assay. The assay also distinguished cytotoxicity changes in degraded NK‐EVs, indicating the ability of the assay to detect the potential loss of sample integrity. Compared to other commonly reported bioassays (i.e., flow cytometry, cell counting, lactate dehydrogenase release assay, DNA‐binding reporter assay and confluence assay), our results support this highly sensitive resazurin‐based viability potency assay as a high‐throughput and quantitative method for assessing NK‐EVs' cytotoxicity against both suspension and adherent cancer models for evaluating NK‐EVs' biotherapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Global outlook on affordability of biotherapeutic drugs.
- Author
-
Rathore, Anurag S., Gardner, Peter J., Chhabra, Hemlata, and Raman, Ruchir
- Subjects
- *
LOW-income countries , *MIDDLE-income countries , *HIGH-income countries , *PRICES , *WORLD health - Abstract
Although biotherapeutic drugs have the potential of transforming the management of many life‐threatening diseases, their affordability and accessibility remain an issue. This study offers an overview of the global affordability of biotherapeutic products. For this, prices for 10 representative biotherapeutic products were examined in 40 countries, including high‐income countries (HICs), upper middle‐income countries (UMICs), lower middle‐income countries (LMICs), and low‐income countries (LICs). The affordability of these biotherapeutics was calculated based on the World Health Organization/Health Action International (WHO/HAI) method. As expected, affordability was found to be better in HICs, followed by UMICs, LMICs, and finally, LICs. Furthermore, based on the trend of per capita income, we predict that in UMICs and LMICs, the affordability of high molecular weight biologics will worsen by 1.5× and 2× by 2030, respectively, and further by 4× and 6× by 2040. On the other hand, affordability will stay nearly the same for people living in HICs in the coming decades. Our analysis suggests that it is imperative that measures be taken to make this class of products more affordable and accessible. Governments can contribute by creating conducive policies. Global institutions like the WHO can play a significant role as well. Finally, manufacturers need to invest in and implement manufacturing innovations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Bioinspired and bioderived nanomedicine for inflammatory bowel disease.
- Author
-
Gazzi, Rafaela, Gelli, Rita, Aleandri, Simone, Carone, Marianna, and Luciani, Paola
- Abstract
Due to its chronic nature and complex pathophysiology, inflammatory bowel disease (IBD) poses significant challenges for treatment. The long‐term therapies for patients, often diagnosed between the ages of 20 and 40, call for innovative strategies to target inflammation, minimize systemic drug exposure, and improve patients' therapeutic outcomes. Among the plethora of strategies currently pursued, bioinspired and bioderived nano‐based formulations have garnered interest for their safety and versatility in the management of IBD. Bioinspired nanomedicine can host and deliver not only small drug molecules but also biotherapeutics, be made gastroresistant and mucoadhesive or mucopenetrating and, for these reasons, are largely investigated for oral administration, while surprisingly less for rectal delivery, recommended first‐line treatment approach for several IBD patients. The use of bioderived nanocarriers, mostly extracellular vesicles (EVs), endowed with unique homing abilities, is still in its infancy with respect to the arsenal of nanomedicine under investigation for IBD treatment. An emerging source of EVs suited for oral administration is ingesta, that is, plants or milk, thanks to their remarkable ability to resist the harsh environment of the upper gastrointestinal tract. Inspired by the unparalleled properties of natural biomaterials, sophisticated avenues for enhancing therapeutic efficacy and advancing precision medicine approaches in IBD care are taking shape, although bottlenecks arising either from the complexity of the nanomedicine designed or from the lack of a clear regulatory pathway still hinder a smooth and efficient translation to the clinics. This article is categorized under:Nanotechnology Approaches to Biology > Nanoscale Systems in Biology [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Transdermal Administration of Nanobody Molecules using Hydrogel‐Forming Microarray Patch Technology: A Unique Delivery Approach.
- Author
-
Hutton, Aaron R. J., Kirkby, Melissa, Van Bogaert, Tom, Casteels, Peter, Nonne, Christelle, De Brabandere, Veronique, de Vyver, Ortwin Van, Vora, Lalit K., Tekko, Ismaiel A., McCarthy, Helen O., and Donnelly, Ryan F.
- Subjects
- *
MICROARRAY technology , *MULTIVALENT molecules , *HYPODERMIC needles , *SPRAGUE Dawley rats , *MOLECULES - Abstract
Nanobody molecules, derived from heavy‐chain only antibodies in camelids, represent the next generation of biotherapeutics. In addition to low immunogenicity, high stability, and potency, their single‐domain format facilitates the construction of multivalent molecules for therapeutic applications. Although predominantly administered using a hypodermic syringe and needle, alternative delivery methods are under investigation. That said, the transdermal route has yet to be explored. Therefore, microarray patch (MAP) technology, offering a potentially high dose, pain‐free transdermal system, is employed in this study. Trivalent Nanobody molecules, with and without half‐life extension (VHH and VHH[HLE]), are formulated into hydrogel‐forming MAPs, with pharmacokinetic parameters assessed in Sprague–Dawley rats. VHH MAPs exhibited a sustained release profile, with a serum concentration of 19 ± 9 ng mL−1 24 h post‐administration. In contrast, a subcutaneous (SC) injection showed faster clearance, with a serum concentration of 1.1 ± 0.4 ng mL−1 at 24 h. For VHH(HLE), both SC and MAP cohorts achieved a maximum serum concentration (Tmax) at 24 h. The MAP cohort displayed a notable increase in VHH(HLE) serum levels between 6–24 h, dropping after MAP removal. This study has exemplified MAPs potential for delivering advanced biologics, indicating the transdermal route's promise for pain‐free, patient‐friendly administration of Nanobody molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Liquid-phase separations coupled with ion mobility-mass spectrometry for next-generation biopharmaceutical analysis.
- Author
-
Makey, Devin M. and Ruotolo, Brandon T.
- Abstract
The pharmaceutical industry continues to expand its search for innovative biotherapeutics. The comprehensive characterization of such therapeutics requires many analytical techniques to fully evaluate critical quality attributes, making analysis a bottleneck in discovery and development timelines. While thorough characterization is crucial for ensuring the safety and efficacy of biotherapeutics, there is a need to further streamline analytical characterization and expedite the overall timeline from discovery to market. This review focuses on recent developments in liquid-phase separations coupled with ion mobility-mass spectrometry (IM-MS) for the development and characterization of biotherapeutics. We cover uses of IM-MS to improve the characterization of monoclonal antibodies, antibody-drug conjugates, host cell proteins, glycans, and nucleic acids. This discussion is based on an extensive literature search using Web of Science, Google Scholar, and SciFinder. IM-MS has the potential to enhance the depth and efficiency of biotherapeutic characterization by providing additional insights into conformational changes, post-translational modifications, and impurity profiles. The rapid timescale of IM-MS positions it well to enhance the information content of existing assays through its facile integration with standard liquid-phase separation techniques that are commonly used for biopharmaceutical analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity
- Author
-
Michel Siegel, Anna-Lena Bolender, Axel Ducret, Johannes Fraidling, Katharina Hartman, Cary M. Looney, Olivier Rohr, Timothy P. Hickling, Hubert Kettenberger, Martin Lechmann, Céline Marban-Doran, and Thomas E. Kraft
- Subjects
immunogenicity ,biotherapeutics ,charge patches ,internalization ,dendritic cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionImmunogenicity, the unwanted immune response triggered by therapeutic antibodies, poses significant challenges in biotherapeutic development. This response can lead to the production of anti-drug antibodies, potentially compromising the efficacy and safety of treatments. The internalization of therapeutic antibodies into dendritic cells (DCs) is a critical factor influencing immunogenicity. Using monoclonal antibodies, with differences in non-specific cellular uptake, as tools to explore the impact on the overall risk of immunogenicity, this study explores how internalization influences peptide presentation and subsequently T cell activation.Materials and methodsTo investigate the impact of antibody internalization on immunogenicity, untargeted toolantibodies with engineered positive or negative charge patches were utilized. Immature monocyte-derived DCs (moDCs), known for their physiologically relevant high endocytic activity, were employed for internalization assays, while mature moDCs were used for MHC-II associated peptide proteomics (MAPPs) assays. In addition to the lysosomal accumulation and peptide presentation, subsequent CD4+ T cell activation has been assessed. Consequently, a known CD4+ T cell epitope from ovalbumin was inserted into the tool antibodies to evaluate T cell activation on a single, shared epitope.ResultsAntibodies with positive charge patches exhibited higher rates of lysosomal accumulation and epitope presentation compared to those with negative charge patches or neutral surface charge. Furthermore, a direct correlation between internalization rate and presentation on MHC-II molecules could be established. To explore the link between internalization, peptide presentation and CD4+ T cell activation, tool antibodies containing the same OVA epitope were used. Previous observations were not altered by the insertion of the OVA epitope and ultimately, an enhanced CD4+ T cell response correlated with increased internalization in DCs and peptide presentation.DiscussionThese findings demonstrate that the biophysical properties of therapeutic antibodies, particularly surface charge, play a crucial role in their internalization into DCs. Antibodies internalized faster and processed by DCs, are also more prone to be presented on their surface leading to a higher risk of triggering an immune response. These insights underscore the importance of considering antibody surface charge and other properties that enhance cellular accumulation during the preclinical development of biotherapeutics to mitigate immunogenicity risks.
- Published
- 2024
- Full Text
- View/download PDF
19. Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics
- Author
-
Michel Siegel, Aman Padamsey, Anna-Lena Bolender, Patrick Hargreaves, Johannes Fraidling, Axel Ducret, Katharina Hartman, Cary M. Looney, Cristina Bertinetti-Lapatki, Olivier Rohr, Timothy P. Hickling, Thomas E. Kraft, and Céline Marban-Doran
- Subjects
immunogenicity ,immunomodulation ,biotherapeutics ,dendritic cells ,assay development ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionImmunogenicity refers to the ability of a substance, such as a therapeutic drug, to elicit an immune response. While beneficial in vaccine development, undesirable immunogenicity can compromise the safety and efficacy of therapeutic proteins by inducing anti-drug antibodies (ADAs). These ADAs can reduce drug bioavailability and alter pharmacokinetics, necessitating comprehensive immunogenicity risk assessments starting at early stages of drug development. Given the complexity of immunogenicity, an integrated approach is essential, as no single assay can universally recapitulate the immune response leading to the formation of anti-drug antibodies.MethodsTo better understand the Dendritic Cell (DC) contribution to immunogenicity, we developed two flow cytometry-based assays: the DC internalization assay and the DC activation assay. Monocyte-derived dendritic cells (moDCs) were generated from peripheral blood mononuclear cells (PBMCs) and differentiated over a five-day period. The internalization assay measured the accumulation rate of therapeutic antibodies within moDCs, while the activation assay assessed the expression of DC activation markers such as CD40, CD80, CD86, CD83, and DC-SIGN (CD209). To characterize these two assays further, we used a set of marketed therapeutic antibodies.ResultsThe study highlights that moDCs differentiated for 5 days from freshly isolated monocytes were more prone to respond to external stimuli. The internalization assay has been shown to be highly sensitive to the molecule tested, allowing the use of only 4 donors to detect small but significant differences. We also demonstrated that therapeutic antibodies were efficiently taken up by moDCs, with a strong correlation with their peptide presentation on MHC-II. On the other hand, by monitoring DC activation through a limited set of activation markers including CD40, CD83, and DC-SIGN, the DC activation assay has the potential to compare a series of compounds. These two assays provide a more comprehensive understanding of DC function in the context of immunogenicity, highlighting the importance of both internalization and activation processes in ADA development.DiscussionThe DC internalization and activation assays described here address key gaps in existing immunogenicity assessment methods by providing specific and reliable measures of DC function. The assays enhance our ability to pre-clinically evaluate the immunogenic potential of biotherapeutics, thereby improving their safety and efficacy. Future work should focus on further validating these assays and integrating them into a holistic immunogenicity risk assessment framework.
- Published
- 2024
- Full Text
- View/download PDF
20. Metabolic Materials from Cyanobacteria and Microalgae: Biotechnology, Biochemistry and Biotherapeutics
- Author
-
Paduvetnaya, Lokitha, Venkatesh, Kamath H., Madhyastha, Harishkumar, Agarwal, Avinash Kumar, Series Editor, Bala, Kiran, editor, Ghosh, Tonmoy, editor, Kumar, Vivek, editor, and Sangwan, Pritam, editor
- Published
- 2024
- Full Text
- View/download PDF
21. Microneedle and Polymeric Films: Delivery of Proteins, Peptides and Nucleic Acids
- Author
-
Wu, Yu, Hutton, Aaron R. J., Pandya, Anjali Kiran, Patravale, Vandana B., Donnelly, Ryan F., Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Editorial Board Member, Seifert, Roland, Editorial Board Member, Wang, KeWei, Editorial Board Member, Schäfer-Korting, Monika, editor, and Schubert, Ulrich S., editor
- Published
- 2024
- Full Text
- View/download PDF
22. A novel front in sustainable microbial management: computational analysis of curcumin and mangiferin's synergistic action against Bacillus anthracis.
- Author
-
Perveen, Kahkashan, Bukhari, Najat A., Alshaikh, Najla A., Kondaveeti, Suresh Babu, Alsulami, Jamilah A., Debnath, Sandip, and Kumarasamy, Vinoth
- Subjects
BACILLUS anthracis ,MANGIFERIN ,CURCUMIN ,MOLECULAR dynamics ,BINDING energy - Abstract
Background: Microorganisms are crucial in our ecosystem, offering diverse functions and adaptability. The UNGA Science Summit has underscored the importance of understanding microbes in alignment with the UN Sustainable Development Goals. Bacillus anthracis poses significant challenges among various microorganisms due to its harmful effects on both soil and public health. Our study employed computational techniques to investigate the inhibitory effects of curcumin and mangiferin on Bacillus anthracis, with the aim of presenting a novel bio-based approach to microbial management. Methods: Employing high-throughput screening, we identified potential binding sites on B. anthracis. Molecular docking revealed that curcumin and mangiferin, when synergistically combined, exhibited strong binding affinities at different sites on the bacterium. Our findings demonstrated a significant drop in binding free energy, indicating a stronger interaction when these compounds were used together. Findings: Results of Molecular docking indicated binding energies of -8.45 kcal/mol for mangiferin, -7.68 kcal/mol for curcumin, and a notably higher binding energy of -19.47 kcal/mol for the combination of mangiferin and curcumin with CapD protein. Molecular dynamics simulations further validated these interactions, demonstrating increased stability and structural changes in the bacterium. Conclusion: This study highlights the effectiveness of natural compounds like curcumin and mangiferin in microbial management, especially against challenging pathogens like B. anthracis. It emphasizes the potential of sustainable, nature-based solutions and calls for further empirical research to expand upon these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle.
- Author
-
Attreed, Sarah E., Silva, Christina, Rodriguez-Calzada, Monica, Mogulothu, Aishwarya, Abbott, Sophia, Azzinaro, Paul, Canning, Peter, Skidmore, Lillian, Nelson, Jay, Knudsen, Nick, Medina, Gisselle N., de los Santos, Teresa, and Segundo, Fayna Díaz-San
- Subjects
CATTLE ,COMBINED vaccines ,BOS ,ANIMAL diseases ,VIRUS diseases ,FOOT & mouth disease - Abstract
Foot-and-mouth disease (FMD) is a vesicular disease of cloven-hoofed animals with devastating economic implications. The current FMD vaccine, routinely used in enzootic countries, requires at least 7 days to induce protection. However, FMD vaccination is typically not recommended for use in non-enzootic areas, underscoring the need to develop new fast-acting therapies for FMD control during outbreaks. Interferons (IFNs) are among the immune system's first line of defense against viral infections. Bovine type III IFN delivered by a replication defective adenovirus (Ad) vector has effectively blocked FMD in cattle. However, the limited duration of protection--usually only 1-3 days post-treatment (dpt)--diminishes its utility as a field therapeutic. Here, we test whether polyethylene glycosylation (PEGylation) of recombinant bovine IFNλ3 (PEGboIFNλ3) can extend the duration of IFN-induced prevention of FMDV infection in both vaccinated and unvaccinated cattle. We treated groups of heifers with PEGboIFNλ3 alone or in combination with an adenovirus-based FMD O1Manisa vaccine (Adt-O1M) at either 3 or 5 days prior to challenge with homologous wild type FMDV. We found that pre-treatment with PEGboIFNλ3 was highly effective at preventing clinical FMD when administered at either time point, with or without co-administration of Adt-O1M vaccine. PEGboIFNλ3 protein was detectable systemically for >10 days and antiviral activity for 4 days following administration. Furthermore, in combination with Adt-O1M vaccine, we observed a strong induction of FMDV-specific IFNγ+ T cell response, demonstrating its adjuvanticity when co-administered with a vaccine. Our results demonstrate the promise of this modified IFN as a pre-exposure prophylactic therapy for use in emergency outbreak scenarios. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. The effect of the composition of polysorbate 80 grades on their physicochemical properties.
- Author
-
Kollamaram, Gayathri and Williams, Gareth R.
- Subjects
- *
POLYSORBATE 80 , *FATTY acids , *EXCIPIENTS - Abstract
Polysorbate 80 is one of the most commonly used surfactants in the formulation of biotherapeutics, particularly those administered intravenously. It comprises a mixture of fatty acids but is not a precisely defined chemical entity. Hence, there are a range of different grades available in the market, all meeting compendial specifications. Polysorbate 80 is known to undergo auto degradation producing protein-damaging by-products, and to contain residual impurities that can have an impact on the stability and integrity of the active ingredients in the formulation. Given the variety of chemical compositions that polysorbate 80 can comprise, the degradation pathway and extent could vary depending on the grade used in the formulation. This study compared the physical and chemical properties of four commercially available polysorbate 80 grades with different degrees of purity and oleic acid content and investigated their degradation profiles. This study did not find any significant differences between the properties or degradation profiles of the four grades investigated. Further studies are underway to understand the formation of other reactive impurities and their impact on the model protein formulations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
25. The NMR signature of maltose-based glycation in full-length proteins.
- Author
-
Defant, Pauline, Regl, Christof, Huber, Christian G., and Schubert, Mario
- Subjects
POST-translational modification ,PROTEINS ,NUCLEAR magnetic resonance spectroscopy ,MALTOSE ,DISACCHARIDES - Abstract
Reducing sugars can spontaneously react with free amines in protein side chains leading to posttranslational modifications (PTMs) called glycation. In contrast to glycosylation, glycation is a non-enzymatic modification with consequences on the overall charge, solubility, aggregation susceptibility and functionality of a protein. Glycation is a critical quality attribute of therapeutic monoclonal antibodies. In addition to glucose, also disaccharides like maltose can form glycation products. We present here a detailed NMR analysis of the Amadori product formed between proteins and maltose. For better comparison, data collection was done under denaturing conditions using 7 M urea-d
4 in D2 O. The here presented correlation patterns serve as a signature and can be used to identify maltose-based glycation in any protein that can be denatured. In addition to the model protein BSA, which can be readily glycated, we present data of the biotherapeutic abatacept containing maltose in its formulation buffer. With this contribution, we demonstrate that NMR spectroscopy is an independent method for detecting maltose-based glycation, that is suited for cross-validation with other methods. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
26. The Microbiome and Pediatric Transplantation.
- Author
-
Elgarten, Caitlin W, Margolis, Elisa B, and Kelly, Matthew S
- Subjects
- *
INFECTION risk factors , *RISK assessment , *IMMUNOLOGICAL tolerance , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *TRANSPLANTATION of organs, tissues, etc. , *GUT microbiome , *GRAFT rejection , *CHILDREN - Abstract
The microbial communities that inhabit our bodies have been increasingly linked to host physiology and pathophysiology. This microbiome, through its role in colonization resistance, influences the risk of infections after transplantation, including those caused by multidrug-resistant organisms. In addition, through both direct interactions with the host immune system and via the production of metabolites that impact local and systemic immunity, the microbiome plays an important role in the establishment of immune tolerance after transplantation, and conversely, in the development of graft-versus-host disease and graft rejection. This review offers a comprehensive overview of the evidence for the role of the microbiome in hematopoietic cell and solid organ transplant complications, drivers of microbiome shift during transplantation, and the potential of microbiome-based therapies to improve pediatric transplantation outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Evaluation of resazurin phenoxazine dye as a highly sensitive cell viability potency assay for natural killer cell‐derived extracellular vesicle‐based cancer biotherapeutics
- Author
-
Frederic St‐Denis‐Bissonnette, Shirley Qiu, Sarah E. Cummings, Melanie Kirkby, Yohannes Haile, Sarah Wassmer, Gauri Muradia, Jelica Mehic, Andrew Stalker, Amit Shrestha, Michele Ardolino, Seung‐Hwan Lee, Dylan Burger, Lisheng Wang, and Jessie R. Lavoie
- Subjects
biotherapeutics ,cancer ,exosome ,extracellular vesicles (EVs) ,natural killer (NK) cells ,potency assay ,Cytology ,QH573-671 - Abstract
Abstract Natural killer cell‐derived extracellular vesicles (NK‐EVs) are candidate biotherapeutics against various cancers. However, standardised potency assays are necessary for a reliable assessment of NK‐EVs' cytotoxicity. This study aims to thoroughly evaluate a highly sensitive resazurin phenoxazine‐based cell viability potency assay (measurement of the cellular redox metabolism) for quantifying the cytotoxicity of NK‐EVs against leukaemia K562 cells (suspension model) and breast cancer MDA‐MB‐231 cells (adherent model) in vitro. The assay was evaluated based on common analytical parameters setforth by regulatory guidelines, including specificity, selectivity,accuracy, precision, linearity, range and stability. Our results revealed that this resazurin‐based cell viability potency assay reliably and reproducibly measured a dose‐response of NK‐EVs’ cytotoxic activity against both cancer models. The assay showed precision with 5% and 20% variation for intra‐run and inter‐run variability. The assay signal showed specificity and selectivity of NK‐EVs against cancer target cells, as evidenced by the diminished viability of cancer cells following a 5‐hour treatment with NK‐EVs, without any detectable interference or background. The linearity analysis of target cancer cells revealed strong linearity for densities of 5000 K562 and 1000 MDA‐MB‐231 cells per test with a consistent range. Importantly, NK‐EVs’ dose‐response for cytotoxicity showed a strong correlation (|ρ| ∼ 0.8) with the levels of known cytotoxic factors associated with the NK‐EVs’ corona (FasL, GNLY, GzmB, PFN and IFN‐γ), thereby validating the accuracy of the assay. The assay also distinguished cytotoxicity changes in degraded NK‐EVs, indicating the ability of the assay to detect the potential loss of sample integrity. Compared to other commonly reported bioassays (i.e., flow cytometry, cell counting, lactate dehydrogenase release assay, DNA‐binding reporter assay and confluence assay), our results support this highly sensitive resazurin‐based viability potency assay as a high‐throughput and quantitative method for assessing NK‐EVs’ cytotoxicity against both suspension and adherent cancer models for evaluating NK‐EVs’ biotherapeutics.
- Published
- 2024
- Full Text
- View/download PDF
28. Transdermal Administration of Nanobody Molecules using Hydrogel‐Forming Microarray Patch Technology: A Unique Delivery Approach
- Author
-
Aaron R. J. Hutton, Melissa Kirkby, Tom Van Bogaert, Peter Casteels, Christelle Nonne, Veronique De Brabandere, Ortwin Van deVyver, Lalit K. Vora, Ismaiel A. Tekko, Helen O. McCarthy, and Ryan F. Donnelly
- Subjects
biotherapeutics ,hydrogel‐forming ,microarray patch ,transdermal ,Materials of engineering and construction. Mechanics of materials ,TA401-492 ,Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
Abstract Nanobody molecules, derived from heavy‐chain only antibodies in camelids, represent the next generation of biotherapeutics. In addition to low immunogenicity, high stability, and potency, their single‐domain format facilitates the construction of multivalent molecules for therapeutic applications. Although predominantly administered using a hypodermic syringe and needle, alternative delivery methods are under investigation. That said, the transdermal route has yet to be explored. Therefore, microarray patch (MAP) technology, offering a potentially high dose, pain‐free transdermal system, is employed in this study. Trivalent Nanobody molecules, with and without half‐life extension (VHH and VHH[HLE]), are formulated into hydrogel‐forming MAPs, with pharmacokinetic parameters assessed in Sprague–Dawley rats. VHH MAPs exhibited a sustained release profile, with a serum concentration of 19 ± 9 ng mL−1 24 h post‐administration. In contrast, a subcutaneous (SC) injection showed faster clearance, with a serum concentration of 1.1 ± 0.4 ng mL−1 at 24 h. For VHH(HLE), both SC and MAP cohorts achieved a maximum serum concentration (Tmax) at 24 h. The MAP cohort displayed a notable increase in VHH(HLE) serum levels between 6–24 h, dropping after MAP removal. This study has exemplified MAPs potential for delivering advanced biologics, indicating the transdermal route's promise for pain‐free, patient‐friendly administration of Nanobody molecules.
- Published
- 2024
- Full Text
- View/download PDF
29. EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening
- Author
-
Ambra Cappelletto, Edoardo Alfì, Nina Volf, Thi Van Anh Vu, Francesca Bortolotti, Giulio Ciucci, Simone Vodret, Marco Fantuz, Martina Perin, Andrea Colliva, Giacomo Rozzi, Matilde Rossi, Giulia Ruozi, Lorena Zentilin, Roman Vuerich, Daniele Borin, Romano Lapasin, Silvano Piazza, Mattia Chiesa, Daniela Lorizio, Luca Triboli, Sandeep Kumar, Gaia Morello, Claudio Tripodo, Maurizio Pinamonti, Giulia Maria Piperno, Federica Benvenuti, Alessandra Rustighi, Hanjoong Jo, Stefano Piccolo, Giannino Del Sal, Alessandro Carrer, Mauro Giacca, and Serena Zacchigna
- Subjects
In vivo screening ,Cancer ,Cell invasiveness ,AAV vectors ,Gene therapy ,Biotherapeutics ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect. Methods We screened an Adeno-Associated Vector secretome library (> 1000 clones) directly in vivo in a mouse model of cancer and validated the therapeutic effect of the first hit, EMID2, in both orthotopic and genetic models of lung and pancreatic cancer. Results EMID2 overexpression inhibited both tumor growth and metastatic dissemination, consistent with prolonged survival of patients with high levels of EMID2 expression in the most aggressive human cancers. Mechanistically, EMID2 inhibited TGFβ maturation and activation of cancer-associated fibroblasts, resulting in more elastic ECM and reduced levels of YAP in the nuclei of cancer cells. Conclusion This is the first in vivo screening, precisely designed to identify proteins able to interfere with cancer cell invasiveness. EMID2 was selected as the most potent protein, in line with the emerging relevance of the tumor extracellular matrix in controlling cancer cell invasiveness and dissemination, which kills most of cancer patients.
- Published
- 2024
- Full Text
- View/download PDF
30. Pulmonary Inhalation of Biotherapeutics: A Systematic Approach to Understanding the Effects of Atomisation Gas Flow Rate on Particle Physiochemical Properties and Retained Bioactivity
- Author
-
Laura Foley, Ahmad Ziaee, Gavin Walker, and Emmet O’Reilly
- Subjects
biotherapeutics ,spray-drying ,atomisation gas flow rate ,enzymatic activity ,particle engineering ,pulmonary delivery ,Pharmacy and materia medica ,RS1-441 - Abstract
The identification of spray-drying processing parameters capable of producing particles suitable for pulmonary inhalation with retained bioactivity underpins the development of inhalable biotherapeutics. Effective delivery of biopharmaceuticals via pulmonary delivery routes such as dry powder inhalation (DPI) requires developing techniques that engineer particles to well-defined target profiles while simultaneously minimising protein denaturation. This study examines the simultaneous effects of atomisation gas flow rate on particle properties and retained bioactivity for the model biopharmaceutical lysozyme. The results show that optimising the interplay between atomisation gas flow rate and excipient concentration enables the production of free-flowing powder with retained bioactivity approaching 100%, moisture content below 4%, and D50 < 4 µm, at yields exceeding 50%. The developed methodologies inform the future design of protein-specific spray-drying parameters for inhalable biotherapeutics.
- Published
- 2024
- Full Text
- View/download PDF
31. Exploring the Multifaceted Therapeutic Potential of Probiotics: A Review of Current Insights and Applications
- Author
-
Chakravarty, Kashyapi, Gaur, Smriti, Kumar, Rohit, Jha, Niraj Kumar, and Gupta, Piyush Kumar
- Published
- 2024
- Full Text
- View/download PDF
32. Unveiling Curvularia tuberculata-induced leaf anomalies in Rhododendron ferrugineum: implications in cultural-ecological conservation and harnessing microbial intervention in socio-economic advancement.
- Author
-
Dhar, Juhita, Hazra, Aishee, Patra, Riddhisha, Kumar, Varun, Subramaniyan, Vetriselvan, Kumarasamy, Vinoth, Mitra, Arup Kumar, Sayed, Amany A., Aleya, Lotfi, El-Demerdash, Fatma M., Almutairi, Mikhlid H., Akash, Shopnil, Abdel-Daim, Mohamed M., Kant, Achal, and Dhara, Bikram
- Subjects
RHODODENDRONS ,CURVULARIA ,PATHOGENIC fungi ,MOUNTAIN ecology ,CULTURAL property ,DISEASE management - Abstract
Introduction: The research focuses on Rhododendron ferrugineum L., Nepal's national flower and Uttarakhand's state tree, thriving in high-altitude mountain ecosystems. Methodology and Result: A study conducted in Himachal Pradesh (Latitude: N 31° 6' 2.0088", Longitude: E 77° 10' 29.9136") identified leaf anomalies resembling rust-like manifestations in R. ferrugineum. These anomalies were traced back to the pathogenic fungus Curvularia tuberculata, marking the first documented case of its impact on R. ferrugineum in India. Discussion: This discovery emphasizes the need for vigilant monitoring, disease management research, and conservation efforts to protect the cultural and ecological significance of this iconic shrub. Beyond its immediate findings, the study introduces a novel dimension to Indian flora by associating C. tuberculata with R. ferrugineum, historically linked to monocotyledonous crops. The research methodology combines traditional microscopic examination with advanced genomic sequencing and phylogenetic analysis, enhancing pathogen identification accuracy. Future prospect: In a broader context, this research aligns with the United Nations Sustainable Development Goals (SDGs) by highlighting the importance of environmental preservation, conservation, and sustainable management. It underscores the intricate interplay between biodiversity, cultural heritage, and the need for holistic solutions. Overall, this study calls for proactive measures to protect R. ferrugineum's cultural and ecological heritage and emphasizes the significance of interdisciplinary approaches in addressing emerging ecological threats. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.
- Author
-
Cappelletto, Ambra, Alfì, Edoardo, Volf, Nina, Vu, Thi Van Anh, Bortolotti, Francesca, Ciucci, Giulio, Vodret, Simone, Fantuz, Marco, Perin, Martina, Colliva, Andrea, Rozzi, Giacomo, Rossi, Matilde, Ruozi, Giulia, Zentilin, Lorena, Vuerich, Roman, Borin, Daniele, Lapasin, Romano, Piazza, Silvano, Chiesa, Mattia, and Lorizio, Daniela
- Subjects
- *
MEDICAL screening , *GENETIC models , *CANCER invasiveness , *EXTRACELLULAR matrix , *CELL nuclei , *BIOSURVEILLANCE - Abstract
Background: New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect. Methods: We screened an Adeno-Associated Vector secretome library (> 1000 clones) directly in vivo in a mouse model of cancer and validated the therapeutic effect of the first hit, EMID2, in both orthotopic and genetic models of lung and pancreatic cancer. Results: EMID2 overexpression inhibited both tumor growth and metastatic dissemination, consistent with prolonged survival of patients with high levels of EMID2 expression in the most aggressive human cancers. Mechanistically, EMID2 inhibited TGFβ maturation and activation of cancer-associated fibroblasts, resulting in more elastic ECM and reduced levels of YAP in the nuclei of cancer cells. Conclusion: This is the first in vivo screening, precisely designed to identify proteins able to interfere with cancer cell invasiveness. EMID2 was selected as the most potent protein, in line with the emerging relevance of the tumor extracellular matrix in controlling cancer cell invasiveness and dissemination, which kills most of cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model.
- Author
-
Masloh, Solene, Chevrel, Anne, Culot, Maxime, Perrocheau, Anaëlle, Kalia, Yogeshvar N., Frehel, Samuel, Gaussin, Rémi, Gosselet, Fabien, Huet, Simon, Zeisser Labouebe, Magali, and Scapozza, Leonardo
- Subjects
- *
LEPTIN receptors , *INTESTINAL barrier function , *INTESTINES , *INTESTINAL absorption , *BIOLOGICALS , *LEPTIN - Abstract
Biotherapeutics exhibit high efficacy in targeted therapy, but their oral delivery is impeded by the harsh conditions of the gastrointestinal (GI) tract and limited intestinal absorption. This article presents a strategy to overcome the challenges of poor intestinal permeability by using a protein shuttle that specifically binds to an intestinal target, the leptin receptor (LepR), and exploiting its capacity to perform a receptor-mediated transport. Our proof-of-concept study focuses on the characterization and transport of robust affinity proteins, known as Nanofitins, across an ex vivo porcine intestinal model. We describe the potential to deliver biologically active molecules across the mucosa by fusing them with the Nanofitin 1-F08 targeting the LepR. This particular Nanofitin was selected for its absence of competition with leptin, its cross-reactivity with LepR from human, mouse, and pig hosts, and its shuttle capability associated with its ability to induce a receptor-mediated transport. This study paves the way for future in vivo demonstration of a safe and efficient oral-to-systemic delivery of targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis.
- Author
-
Grempler, Rolf, Ahlberg, Jennifer, Germovsek, Eva, Gupta, Priyanka, Li, Hua, Pilvankar, Minu, Sharma, Ashish, Stopfer, Peter, and Hansel, Steven
- Abstract
Introduction: Accurate predictions of pharmacokinetics and efficacious doses for biologics in humans are critical for selecting appropriate first-in-human starting doses and dose ranges and for estimating clinical material needs and cost of goods. This also impacts clinical feasibility, particularly for subcutaneously administered biologics. Methods: We performed a comprehensive comparison between predicted and observed clearances and doses in humans for a set of 22 biologic drugs developed at Boehringer Ingelheim (BI) over the last 2 decades. The analysis included biologics across three therapeutic areas comprising a wide variety of modalities: mono- and bispecific monoclonal antibodies (mAbs) and nanobodies and a Fab fragment. Results: Our analysis showed that observed clearances in humans were within twofold of predicted clearances for 17 out of 20 biologics (85%). Six biologics had uncharacteristically high observed human clearances (range 32–280 mL/h) for their respective molecular classes, impacting their clinical developability. For three molecules, molecular characteristics contributed to the high clearance. Clinically selected doses were within twofold of predicted for 58% of projects. With 42% and 25% of projects selecting clinical doses higher than two- or threefold the predicted value, respectively, the importance of better understanding not only the pharmacokinetic (PK) but also the predictivity of pharmacodynamic models is highlighted. Conclusions: We provide a clinical pharmacology perspective on the commonly accepted twofold range of human clearance predictions as well as the implications of higher than predicted targeted efficacious plasma concentration on clinical development. Finally, an analysis of key success factors for biologics at BI was conducted, which may be relevant for the entire pharmaceutical industry. This is one of the largest retrospective analyses for biologics and provides further evidence that successful predictions of human PK and efficacious dose will be further facilitated by gathering key translational data early in research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Designer probiotics: Opening the new horizon in diagnosis and prevention of human diseases.
- Author
-
Debnath, Nabendu, Yadav, Pooja, Mehta, Praveen K., Gupta, Priyamvada, Kumar, Deepak, Kumar, Ashwani, Gautam, Vibhav, and Yadav, Ashok K.
- Abstract
Probiotic microorganisms have been used for therapeutic purposes for over a century, and recent advances in biotechnology and genetic engineering have opened up new possibilities for developing therapeutic approaches using indigenous probiotic microorganisms. Diseases are often related to metabolic and immunological factors, which play a critical role in their onset. With the help of advanced genetic tools, probiotics can be modified to produce or secrete important therapeutic peptides directly into mucosal sites, increasing their effectiveness. One potential approach to enhancing human health is through the use of designer probiotics, which possess immunogenic characteristics. These genetically engineered probiotics hold promise in providing novel therapeutic options. In addition to their immunogenic properties, designer probiotics can also be equipped with sensors and genetic circuits, enabling them to detect a range of diseases with remarkable precision. Such capabilities may significantly advance disease diagnosis and management. Furthermore, designer probiotics have the potential to be used in diagnostic applications, offering a less invasive and more cost‐effective alternative to conventional diagnostic techniques. This review offers an overview of the different functional aspects of the designer probiotics and their effectiveness on different diseases and also, we have emphasized their limitations and future implications. A comprehensive understanding of these functional attributes may pave the way for new avenues of prevention and the development of effective therapies for a range of diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. A novel front in sustainable microbial management: computational analysis of curcumin and mangiferin’s synergistic action against Bacillus anthracis
- Author
-
Kahkashan Perveen, Najat A. Bukhari, Najla A. Alshaikh, Suresh Babu Kondaveeti, Jamilah A. Alsulami, Sandip Debnath, and Vinoth Kumarasamy
- Subjects
antibiotics ,biotherapeutics ,mangiferin ,curcumin ,synthetic biology ,molecular docking ,Microbiology ,QR1-502 - Abstract
BackgroundMicroorganisms are crucial in our ecosystem, offering diverse functions and adaptability. The UNGA Science Summit has underscored the importance of understanding microbes in alignment with the UN Sustainable Development Goals. Bacillus anthracis poses significant challenges among various microorganisms due to its harmful effects on both soil and public health. Our study employed computational techniques to investigate the inhibitory effects of curcumin and mangiferin on Bacillus anthracis, with the aim of presenting a novel bio-based approach to microbial management.MethodsEmploying high-throughput screening, we identified potential binding sites on B. anthracis. Molecular docking revealed that curcumin and mangiferin, when synergistically combined, exhibited strong binding affinities at different sites on the bacterium. Our findings demonstrated a significant drop in binding free energy, indicating a stronger interaction when these compounds were used together.FindingsResults of Molecular docking indicated binding energies of −8.45 kcal/mol for mangiferin, −7.68 kcal/mol for curcumin, and a notably higher binding energy of −19.47 kcal/mol for the combination of mangiferin and curcumin with CapD protein. Molecular dynamics simulations further validated these interactions, demonstrating increased stability and structural changes in the bacterium.ConclusionThis study highlights the effectiveness of natural compounds like curcumin and mangiferin in microbial management, especially against challenging pathogens like B. anthracis. It emphasizes the potential of sustainable, nature-based solutions and calls for further empirical research to expand upon these findings.
- Published
- 2024
- Full Text
- View/download PDF
38. Unveiling Curvularia tuberculata-induced leaf anomalies in Rhododendron ferrugineum: implications in cultural-ecological conservation and harnessing microbial intervention in socio-economic advancement
- Author
-
Juhita Dhar, Aishee Hazra, Riddhisha Patra, Varun Kumar, Vetriselvan Subramaniyan, Vinoth Kumarasamy, Arup Kumar Mitra, Amany A. Sayed, Lotfi Aleya, Fatma M. El-Demerdash, Mikhlid H. Almutairi, Shopnil Akash, Mohamed M. Abdel-Daim, Achal Kant, and Bikram Dhara
- Subjects
plant pathology ,biotherapeutics ,microbe-assisted bioremediation ,synthetic biology ,leaf infection ,R. ferrugineum ,Microbiology ,QR1-502 - Abstract
IntroductionThe research focuses on Rhododendron ferrugineum L., Nepal’s national flower and Uttarakhand’s state tree, thriving in high-altitude mountain ecosystems.Methodology and ResultA study conducted in Himachal Pradesh (Latitude: N 31° 6’ 2.0088”, Longitude: E 77° 10’ 29.9136”) identified leaf anomalies resembling rust-like manifestations in R. ferrugineum. These anomalies were traced back to the pathogenic fungus Curvularia tuberculata, marking the first documented case of its impact on R. ferrugineum in India.DiscussionThis discovery emphasizes the need for vigilant monitoring, disease management research, and conservation efforts to protect the cultural and ecological significance of this iconic shrub. Beyond its immediate findings, the study introduces a novel dimension to Indian flora by associating C. tuberculata with R. ferrugineum, historically linked to monocotyledonous crops. The research methodology combines traditional microscopic examination with advanced genomic sequencing and phylogenetic analysis, enhancing pathogen identification accuracy.Future prospectIn a broader context, this research aligns with the United Nations Sustainable Development Goals (SDGs) by highlighting the importance of environmental preservation, conservation, and sustainable management. It underscores the intricate interplay between biodiversity, cultural heritage, and the need for holistic solutions. Overall, this study calls for proactive measures to protect R. ferrugineum’s cultural and ecological heritage and emphasizes the significance of interdisciplinary approaches in addressing emerging ecological threats.
- Published
- 2024
- Full Text
- View/download PDF
39. Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model
- Author
-
Solene Masloh, Anne Chevrel, Maxime Culot, Anaëlle Perrocheau, Yogeshvar N. Kalia, Samuel Frehel, Rémi Gaussin, Fabien Gosselet, Simon Huet, Magali Zeisser Labouebe, and Leonardo Scapozza
- Subjects
biotherapeutics ,permeability ,shuttle ,leptin receptor ,Nanofitins ,ex vivo ,Pharmacy and materia medica ,RS1-441 - Abstract
Biotherapeutics exhibit high efficacy in targeted therapy, but their oral delivery is impeded by the harsh conditions of the gastrointestinal (GI) tract and limited intestinal absorption. This article presents a strategy to overcome the challenges of poor intestinal permeability by using a protein shuttle that specifically binds to an intestinal target, the leptin receptor (LepR), and exploiting its capacity to perform a receptor-mediated transport. Our proof-of-concept study focuses on the characterization and transport of robust affinity proteins, known as Nanofitins, across an ex vivo porcine intestinal model. We describe the potential to deliver biologically active molecules across the mucosa by fusing them with the Nanofitin 1-F08 targeting the LepR. This particular Nanofitin was selected for its absence of competition with leptin, its cross-reactivity with LepR from human, mouse, and pig hosts, and its shuttle capability associated with its ability to induce a receptor-mediated transport. This study paves the way for future in vivo demonstration of a safe and efficient oral-to-systemic delivery of targeted therapies.
- Published
- 2024
- Full Text
- View/download PDF
40. Assessment of subcutaneously administered insulins using in vitro release cartridge: Medium composition and albumin binding.
- Author
-
Bock, Frederik, Zivlaei, Nadia, Nguyen, Anna Thu Hoai, Larsen, Susan Weng, Lu, Xujin, and Østergaard, Jesper
- Subjects
- *
INSULIN therapy , *INSULIN derivatives , *SUBCUTANEOUS injections , *ALBUMINS , *SERUM albumin , *INSULIN - Abstract
[Display omitted] Biotherapeutics is the fastest growing class of drugs administered by subcutaneous injection. In vitro release testing mimicking physiological conditions at the injection site may guide formulation development and improve biopredictive capabilities. Here, an in vitro release cartridge (IVR cartridge) comprising a porous agarose matrix emulating subcutaneous tissue was explored. The objective was to assess effects of medium composition and incorporation of human serum albumin into the matrix. Drug disappearance was assessed for solution, suspension and in situ precipitating insulin products (Actrapid, Levemir, Tresiba, Mixtard 30, Insulatard, Lantus) using the flow-based cartridge. UV–Vis imaging and light microscopy visualized dissolution, precipitation and albumin binding phenomena at the injection site. Divalent cations present in the release medium resulted in slower insulin disappearance for suspension-based and in situ precipitating insulins. Albumin-binding acylated insulin analogs exhibited rapid disappearance from the cartridge; however, sustained retention was achieved by coupling albumin to the matrix. An in vitro-in vivo relation was established for the non-albumin-binding insulins. The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Carrier-Guided Proteome Analysis in a High Protein Background: An Improved Approach to Host Cell Protein Identification.
- Author
-
Karmani D, Seifihesar N, Sultonova M, Blackmore B, Paulo JA, Harty M, and Murphy JP
- Abstract
Many shotgun proteomics experiments are negatively influenced by highly abundant proteins, such as those measuring residual host cell proteins (HCP) amidst highly abundant recombinant biotherapeutic or plasma proteins amidst albumin and immunoglobulins. While western blotting and ELISAs can reveal the presence of specific low abundance proteins from highly abundant background proteins, mass spectrometry approaches are required to define the low abundance protein composition in these scenarios. The challenge in detecting low abundance proteins in a high protein background by standard shotgun approaches is that spectra are often not triggered on their peptides in data dependent acquisition methods but rather on the highly abundant background peptides. Here, we use tandem mass tags (TMT) to introduce a carrier proteome approach to enhance the detection of proteins, such as from residual host cell proteomes amidst a highly abundant background. Using a mixture of bovine serum albumin (BSA) and E. coli as a mock high background/low abundance target protein formulation, we demonstrate proof-of-principle experiments allowing the improved detection of target proteins amidst a high protein background. While we observed significant coisolation interference, we mitigated it by using a spike-in interference detection TMT channel. Finally, we use the approach to identify 300 residual E. coli proteins from a protein A pulldown of a human IgG antibody, demonstrating that it may be applicable to analysis of HCPs in biotherapeutic protein formulations.
- Published
- 2024
- Full Text
- View/download PDF
42. The effect of temperature-dependent drug viscosity on needle-free jet injection.
- Author
-
William McKeage J, Janet Full H, Zheng Hao Tan A, and James Taberner A
- Abstract
Highly viscous drugs cannot be delivered through a needle. Typically, this means that these drugs are formulated at lower concentrations, demanding higher delivery volumes, which often must be delivered intravenously. Jet injection may provide an important solution for viscous drug delivery. Jet injection is a needle-free drug delivery technique whereby a liquid drug is formed into a hair-thin (∼200 µm) high-speed (>100 m/s) jet that penetrates and delivers itself into tissue. While it may seem that it would be just as difficult to form a viscous drug into a high-speed jet as it is to force it down a needle, this is not the case. Recent work has revealed that 'viscous-heating' during jet injection can result in significant temperature increase, and resultant viscosity decrease, in a thin outer-layer of the jet; this phenomenon effectively results in the drug 'self-lubricating' as it passes through a jet injection orifice. Despite the potential for this finding to revolutionise the subcutaneous delivery of high-viscosity drugs, little further work in this area has since been reported on. In this work we develop finite element models of needle-free injection to investigate how viscous heating affects jet production, how heat exchange with the orifice material influences this process, and to what extent jet production is affected by the initial temperature of the fluid. We then conduct novel high-speed measurements of jet and orifice temperature changes due to viscous heating. We find that viscous heating is responsible for approximately doubling the speed of jets that can be produced with very viscous fluid (1 Pa·s) at room temperature. The thermal conductivity of the orifice can transfer heat away from the perimeter of the jet, and thus reduce the lubricating effect of viscous heating. We then show that by preheating 99 % glycerol (1 Pa·s) from 7 °C to 37 °C the jet speed can be increased 6-fold. We also demonstrate the successful delivery of a very viscous glycerol solution using preheated jet injection into ex vivo porcine tissue. Given that 99 % glycerol is 10- to 100-fold more viscous than current protein therapeutics, our findings demonstrate the potential for jet injection, with or without additional drug preheating, to deliver drug formulations, needle-free, that are much more viscous than those currently delivered through needles., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Andrew Taberner reports financial support was provided by New Zealand Ministry of Business Innovation and Employment. Andrew Taberner reports a relationship with Portal Instruments Inc that includes: equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. Regulatory Verification by Health Canada of Content in Recombinant Human Insulin, Human Insulin Analog, and Porcine Insulin Drug Products in the Canadian Market Using Validated Pharmacopoeial Methods Over Nonvalidated Approaches.
- Author
-
Lorbetskie B, Bigelow S, Walrond L, Klein AV, Loo SM, Green N, Rosu-Myles M, Zhang X, Lu H, Girard M, and Sauvé S
- Subjects
- Canada, Humans, Swine, Insulin analogs & derivatives, Animals, Chromatography, High Pressure Liquid methods, Recombinant Proteins, Insulin, Long-Acting, Reproducibility of Results, Insulin Detemir, Hypoglycemic Agents analysis
- Abstract
Background: For diabetes mellitus treatment plans, the consistency and quality of insulin drug products are crucial for patient well-being. Because biologic drugs, such as insulin, are complex heterogeneous products, the methods for drug product evaluation should be carefully validated for use. As such, these criteria are rigorously evaluated and monitored by national authorities. Consequently, reports that describe significantly lower insulin content than their label claims are a concern. This issue was raised by a past publication analyzing insulin drug products available in Canada, and, as a result, consumers and major patient organizations have requested clarification., Methods: To address these concerns, this study independently analyzed insulin drug products purchased from local Canadian pharmacies-including human insulin, insulin analogs, and porcine insulin-by compendial and noncompendial reversed-phase high-performance liquid chromatography (RP-HPLC) methods., Results: We demonstrated the importance of using methods fit for purpose when assessing insulin quality. In a preliminary screen, the expected insulin peak was seen in all products except two insulin analogs-insulin detemir and insulin degludec. Further investigation showed that this was not caused by low insulin content but insufficient solvent conditions, which demonstrated the necessity for methods to be adequately validated for product-specific use. When drug products were appropriately assessed for content using the validated type-specific compendial RP-HPLC methods for insulin quantitation, values agreed with the label claim content., Conclusions: Because insulin drug products are used daily by over a million Canadians, it is important that researchers and journals present data using methods fit for purpose and that readers evaluate such reports critically., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
44. Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives.
- Author
-
Singh, Santanu, Kachhawaha, Kajal, and Singh, Sumit K.
- Subjects
- *
MONOCLONAL antibodies , *BISPECIFIC antibodies , *PRODUCT elimination , *REGULATORY approval , *THERAPEUTICS , *ANTIBODY-drug conjugates , *IMMUNOGLOBULINS - Abstract
[Display omitted] Biotherapeutics hold great promise for the treatment of several diseases and offer innovative possibilities for new treatments that target previously unaddressed medical needs. Despite successful transitions from preclinical to clinical stages and regulatory approval, there are instances where adverse reactions arise, resulting in product withdrawals. As a result, it is essential to conduct thorough evaluations of safety and effectiveness on an individual basis. This article explores current practices, challenges, and future approaches in conducting comprehensive preclinical assessments to ensure the safety and efficacy of biotherapeutics including monoclonal antibodies, toxin-conjugates, bispecific antibodies, single-chain antibodies, Fc-engineered antibodies, antibody mimetics, and siRNA-antibody/peptide conjugates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Structural biology of flavivirus NS1 protein and its antibody complexes.
- Author
-
Alvin Chew, Bing Liang, Pan, Qi, Hu, Hongli, and Luo, Dahai
- Subjects
- *
VIRAL proteins , *FLAVIVIRUSES , *BIOLOGY , *HIGH density lipoproteins , *MOSQUITO control , *MONOCLONAL antibodies , *VIRAL genomes , *VIRAL nonstructural proteins - Abstract
The genus of flavivirus includes many mosquito-borne human pathogens, such as Zika (ZIKV) and the four serotypes of dengue (DENV1-4) viruses, that affect billions of people as evidenced by epidemics and endemicity in many countries and regions in the world. Among the 10 viral proteins encoded by the viral genome, the nonstructural protein 1 (NS1) is the only secreted protein and has been used as a diagnostic biomarker. NS1 has also been an attractive target for its biotherapeutic potential as a vaccine antigen. This review focuses on the recent advances in the structural landscape of the secreted NS1 (sNS1) and its complex with monoclonal antibodies (mAbs). NS1 forms an obligatory dimer, and upon secretion, it has been reported to be hexametric (trimeric dimers) that could dissociate and bind to the epithelial cell membrane. However, high-resolution structural information has been missing about the high-order oligomeric states of sNS1. Several cryoEM studies have since shown that DENV and ZIKV recombinant sNS1 (rsNS1) are in dynamic equilibrium of dimer-tetramer-hexamer states, with tetramer being the predominant form. It was recently revealed that infection-derived sNS1 (isNS1) forms a complex of the NS1 dimer partially embedded in a High-Density Lipoprotein (HDL) particle. Structures of NS1 in complexes with mAbs have also been reported which shed light on their protective roles during infection. The biological significance of the diversity of NS1 oligomeric states remains to be further studied, to inform future research on flaviviral pathogenesis and the development of therapeutics and vaccines. Given the polymorphism of flavivirus NS1 across sample types with variations in antigenicity, we propose a nomenclature to accurately define NS1 based on the localization and origin. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Decoupling Fluorous Protein Coatings Yield Heat-Stable and Intrinsically Sterile Bioformulations.
- Author
-
Singh H, Lawanprasert A, Utkarsh, Pimcharoen S, Dewan A, Rahoi D, Kirimanjeswara GS, and Medina SH
- Subjects
- Animals, Mice, Proteins chemistry, Proteins metabolism, Coated Materials, Biocompatible chemistry, Coated Materials, Biocompatible pharmacology, Hot Temperature
- Abstract
Thermal inactivation is a major bottleneck to the scalable production, storage, and transportation of protein-based reagents and therapies. Failures in temperature control both compromise protein bioactivity and increase the risk of microorganismal contamination. Herein, we report the rational design of fluorochemical additives that promiscuously bind to and coat the surfaces of proteins to enable their stable dispersion within fluorous solvents. By replacing traditional aqueous liquids with fluorinated media, this strategy conformationally rigidifies proteins to preserve their structure and function at extreme temperatures (≥90 °C). We show that fluorous protein formulations resist contamination by bacterial, fungal, and viral pathogens, which require aqueous environments for survival, and display equivalent serum bioavailability to standard saline samples in animal models. Importantly, by designing dispersants that decouple from the protein surface in physiologic solutions, we deliver a fluorochemical formulation that does not alter the pharmacologic function or safety profile of the functionalized protein in vivo . As a result, this nonaqueous protein storage paradigm is poised to open technological opportunities in the design of shelf-stable protein reagents and biopharmaceuticals.
- Published
- 2024
- Full Text
- View/download PDF
47. Bioinspired and bioderived nanomedicine for inflammatory bowel disease.
- Author
-
Gazzi R, Gelli R, Aleandri S, Carone M, and Luciani P
- Subjects
- Humans, Animals, Extracellular Vesicles metabolism, Drug Delivery Systems, Mice, Inflammatory Bowel Diseases drug therapy, Nanomedicine
- Abstract
Due to its chronic nature and complex pathophysiology, inflammatory bowel disease (IBD) poses significant challenges for treatment. The long-term therapies for patients, often diagnosed between the ages of 20 and 40, call for innovative strategies to target inflammation, minimize systemic drug exposure, and improve patients' therapeutic outcomes. Among the plethora of strategies currently pursued, bioinspired and bioderived nano-based formulations have garnered interest for their safety and versatility in the management of IBD. Bioinspired nanomedicine can host and deliver not only small drug molecules but also biotherapeutics, be made gastroresistant and mucoadhesive or mucopenetrating and, for these reasons, are largely investigated for oral administration, while surprisingly less for rectal delivery, recommended first-line treatment approach for several IBD patients. The use of bioderived nanocarriers, mostly extracellular vesicles (EVs), endowed with unique homing abilities, is still in its infancy with respect to the arsenal of nanomedicine under investigation for IBD treatment. An emerging source of EVs suited for oral administration is ingesta, that is, plants or milk, thanks to their remarkable ability to resist the harsh environment of the upper gastrointestinal tract. Inspired by the unparalleled properties of natural biomaterials, sophisticated avenues for enhancing therapeutic efficacy and advancing precision medicine approaches in IBD care are taking shape, although bottlenecks arising either from the complexity of the nanomedicine designed or from the lack of a clear regulatory pathway still hinder a smooth and efficient translation to the clinics. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology., (© 2024 The Author(s). WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
48. Optimization of elution conditions and comparison of emerging biocompatible columns on the resolving power and detection sensitivity of oligonucleotides by ion-pairing reversed-phase liquid chromatography mass spectrometry.
- Author
-
Bui, Quang-Dong, Deschrijver, Tiny, Noten, Bart, Verluyten, Willy, Vervoort, Nico, and Eeltink, Sebastiaan
- Subjects
- *
LIQUID chromatography-mass spectrometry , *OLIGONUCLEOTIDES , *ION mobility , *TANDEM mass spectrometry , *COUNTER-ions , *NUCLEOTIDE sequence - Abstract
• Effects of ion-pairing agent and counter ion on peak capacity were investigated. • The system configuration was fine-tuned to enhance resolving power. • ACN in IP-RPLC provides better chromatographic resolution than MeOH. • Column comparison was conducted at the kinetic performance limit (1000 bar). • Sub-minute separation and high-resolution analysis with coupled columns are demonstrated. A generic performance comparison strategy has been developed to evaluate the impact of mobile-phase additives (ion-pairing agent / counter ion systems), distinct stationary phases on resulting resolving power, and MS detectability of oligonucleotides and their critical impurities in gradient IP-RPLC. Stationary-phase considerations included particle type (core-shell vs. fully porous particles), particle diameter, and pore size. Separations were carried out at 60°C to optimize mass transfer (C-term). The incorporation of an active column preheater mitigated thermal mismatches, leading to narrower peaks and overcoming peak splitting. Acetonitrile as organic modifier outweighed methanol in terms of peak-capacity generation and yielded a 30% lower back pressure. Performance screening experiments were conducted varying ion-pairing agents and counter ions, while adjusting gradient span achieved an equivalent effective retention window. Hexafluoromethylisopropanol yielded superior chromatographic resolution, whereas hexafluoroisopropanol yielded significantly higher MS detection sensitivity. The 1.7 µm core-shell particle columns with 100 Å pores provided maximum resolving power for small (15–35 mers) oligonucleotides. Sub-min analysis for 15–35 polyT ladders was achieved operating a 50 mm long column at the kinetic performance limits. High-resolution separations between a 21-mer modified RNA sequence oligonucleotides and its related (shortmer and phosphodiester) impurities and complementary strand were obtained using a coupled column set-up with a total length of 450 mm. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Development and validation of online SPE purification coupled to HILIC-fluorescence-MS analysis for the characterization of N-glycans.
- Author
-
Helali, Yosra, Bourez, Axelle, Marchant, Arnaud, Vander Heyden, Yvan, Van Antwerpen, Pierre, and Delporte, Cedric
- Subjects
- *
SOLID phase extraction , *GLYCOPROTEINS , *CHEMICAL purification - Abstract
N-glycans of therapeutic glycoproteins is a critical quality attribute to be addressed. We developed a sensitive method for N-glycan characterization using procainamide (ProcA) labelling and online solid phase extraction (online SPE). N-glycans were enzymatically released, then labeled with ProcA and cleaned up via the online SPE using HILIC chemistry (online HILIC SPE). Two preparation protocols were optimized: a short one (1 h 30) and a long one (18 h). Furthermore, the developed approach was compared to RapiFluor-MS (RFMS) kit (from Waters) and to InstantPC kit (from Agilent) which both include a classical HILIC μElution plate SPE purification. Samples were analyzed using HILIC separation coupled to fluorescence and MS detection (HILIC-FLD-MS) with or without the online HILIC SPE. During the validation, repeatability, intermediate precision, stability, response function and injection volume were tested. Human IgG mix (Multigam®) and NIST mAb standard were used as references as their glycoprofiles are well described. A comparison of three batches of a rituximab biosimilar (Truxima®) and one batch of its originator (MabThera®) was also performed. Online HILIC SPE sample cleanup shows a higher sensitivity and repeatability compared to the classical HILIC μElution SPE. Our online HILIC SPE approach also offers the highest MS signal compared to both commercial kits. However, InstantPC shows the highest FLD signal. The analyses of rituximab samples were in line with the literature showing the efficiency of the method for N-glycan monitoring of biotherapeutics. In conclusion, the results demonstrated the usefulness and ease of application of the developed protocol with the online HILIC SPE purification. [Display omitted] • Sensitive, repeatable and cost-effective online SPE cleanup for N-glycans analysis. • Procainamide labelling of N-glycans. • Online SPE coupled to "classical" HILIC separation with FLD and MS detections. • Approach was validated and tested on the NIST standard and biotherapeutics. • The approach is more sensitive than two commercial kits for MS detection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Bioprocessing of inclusion bodies from E. coli. to produce bioactive recombinant proteins.
- Author
-
Rani, Abhilasha K., Katiyar, Richa, and Rathore, Anurag S.
- Subjects
- *
ESCHERICHIA coli , *RECOMBINANT proteins , *CELLULAR inclusions , *MANUFACTURING processes - Abstract
Recombinant protein production has revolutionized healthcare with biopharmaceutical products, dominating the pharmaceutical pipelines today. E. coli remains one of the most used bacterial hosts for this purpose. Recombinant proteins in E. coli can be either expressed as a soluble or insoluble fraction, depending on the expression strategy. The insoluble fraction of expressed protein is aggregated as inclusion bodies (IBs) in the cytoplasm. Retrieving active, correctly folded protein from the IBs becomes a major challenge for the manufacturer, with considerable efforts spent on optimization of various upstream and downstream approaches. In this review, major advances and challenges associated with the upstream and downstream processing of recombinant protein production in the form of inclusion bodies in the E. coli host system have been summarized. [Display omitted] • E. coli. is a preferred host for the manufacturing of recombinant proteins. • The inclusion bodies (IBs) production is a significant approach to produce recombinat proteins. • An efficent optimization of IBs production and their processing improve their quantity and quality of rPs. • Recent advances and challenges associated with the use of IBs have been summarized in the present article. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.